63985-67-1Relevant articles and documents
Improved cyclobutyl nabilone analogs as potent CB1 receptor agonists
Papanastasiou, Ioannis P.,Georgiadis, Markos-Orestis,Iliopoulos-Tsoutsouvas, Christos,Paronis, Carol A.,Brust, Christina A.,Tran, Ngan K.,Ji, Lipin,Ma, Xiaoyu,Wood, JodiAnne T.,Zvonok, Nikolai,Tong, Fei,Bohn, Laura M.,Nikas, Spyros P.,Makriyannis, Alexandros
supporting information, (2022/01/20)
In earlier work, we explored the SAR for the C3 side chain pharmacophore in the hexahydrocannabinol template represented by the drug nabilone, which resulted in the development of AM2389. In an effort for further optimization, we have merged features of n
2-CYCLOALKYL RESORCINOL CANNABINERGIC LIGANDS
-
Paragraph 0179, (2014/05/07)
The present invention relates to novel 2-cycloalkyl resorcinol compounds; to pharmaceutical compositions comprising the compounds; and to methods of preparing the compounds and uses thereof. The disclosed compounds can bind to and modulate the cannabinoid
Novel 1′,1′-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist
Nikas, Spyros P.,Alapafuja, Shakiru O.,Papanastasiou, Ioannis,Paronis, Carol A.,Shukla, Vidyanand G.,Papahatjis, Demetris P.,Bowman, Anna L.,Halikhedkar, Aneetha,Han, Xiuwen,Makriyannis, Alexandros
experimental part, p. 6996 - 7010 (2010/12/18)
In pursuit of a more detailed understanding of the structural requirements for the key side chain cannabinoid pharmacophore, we have extended our SAR to cover a variety of conformationally modified side chains within the 9-keto and 9-hydroxyl tricyclic st